Results 291 to 300 of about 20,131,715 (394)

Prediction Model for Risk of Hepatocellular Carcinoma After Hepatitis C Viral Eradication. [PDF]

J Hepatocell Carcinoma
Hsu WF, Lo CC, Tseng KC, Lai HC, Chen CY, Peng CY.   +5 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Results of a fast-track HIV and hepatitis C screening protocol in Barcelona, Spain. [PDF]

PLoS One
Chivite I, Guilera V, Callau P, Aguiló R, de Lazzari E, Merino MJ, Diaz L, Carrodeguas A, González-Sánchez JL, Mallolas J.   +9 more
europepmc   +1 more source

Natural evolution of hepatitis C virus infection in hemodialysis Tunisian patients and CTLA-4 SNP's

, 2015
Leila Ksiaa Cheikhrouhou, Yousr Lakhoua-Gorgi, Imen Sfar, Salwa Jendoubi-Ayed, Houda Aouadi, Mouna Makhlouf, K. Ayed, T. Ben Abdallah   +7 more
openalex   +2 more sources

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Qualitative evaluation of the barriers and facilitators to a retrospective hepatitis C virus patient re-engagement exercise in England . [PDF]

BMJ Open
Stuart A, Hörst C, Etoori D, Lorencatto F, Rosenberg W, Lowndes C, Simmons R, Mandal S, Gillyon-Powell M, Desai M.   +9 more
europepmc   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source

Plasma Fibulin-5 as a Novel Marker for Advanced Fibrosis in Chronic Hepatitis C. [PDF]

Gastro Hep Adv
Yasui Y, Sato-Matsubara M, Enomoto M, Matsubara T, Kosugi M, Inoue K, Hoang TH, Yuasa H, Fujii H, Daikoku A, Ikura Y, Kawamura E, Uchida-Kobayashi S, Tamori A, Kawada N.   +14 more
europepmc   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source